146 related articles for article (PubMed ID: 37355392)
61. [Radical Chemoradiotherapy for Recurrent Esophageal Cancer after Curative Esophagectomy].
Nakajima T; Ogata T; Nomiya T; Nonaka T; Nakayama Y; Kano K; Maezawa Y; Segami K; Ikeda K; Sato T; Cho H; Yoshikawa T
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1564-1566. PubMed ID: 28133058
[TBL] [Abstract][Full Text] [Related]
62. Association between time interval from neoadjuvant chemoradiotherapy to surgery and complete histological tumor response in esophageal and gastroesophageal junction cancer: a national cohort study.
Klevebro F; Nilsson K; Lindblad M; Ekman S; Johansson J; Lundell L; Ndegwa N; Hedberg J; Nilsson M
Dis Esophagus; 2020 May; 33(5):. PubMed ID: 31676895
[TBL] [Abstract][Full Text] [Related]
63. Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: a meta-analysis.
Jin HL; Zhu H; Ling TS; Zhang HJ; Shi RH
World J Gastroenterol; 2009 Dec; 15(47):5983-91. PubMed ID: 20014464
[TBL] [Abstract][Full Text] [Related]
64. Outcomes for Esophageal Squamous Cell Carcinoma Treated with Curative Intent in a Western Cohort: Should Multimodal Therapy Be the Gold Standard?
Sheil F; Donohoe CL; King S; O'Toole D; Cunningham M; Cuffe S; Ravi N; Reynolds JV
World J Surg; 2018 May; 42(5):1485-1495. PubMed ID: 29075858
[TBL] [Abstract][Full Text] [Related]
65. Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749).
Tachezy M; Gebauer F; Petersen C; Arnold D; Trepel M; Wegscheider K; Schafhausen P; Bockhorn M; Izbicki JR; Yekebas E
BMC Cancer; 2014 Jun; 14():411. PubMed ID: 24906700
[TBL] [Abstract][Full Text] [Related]
66. Recurrence patterns and associated factors of locoregional failure following neoadjuvant chemoradiation and surgery for esophageal cancer.
Blackham AU; H Naqvi SM; Schell MJ; Jin W; Gangi A; Almhanna K; Fontaine JP; Hoffe SE; Frakes J; Venkat P; Pimiento JM
J Surg Oncol; 2018 Feb; 117(2):150-159. PubMed ID: 28833197
[TBL] [Abstract][Full Text] [Related]
67. Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery.
Hamai Y; Hihara J; Emi M; Furukawa T; Murakami Y; Nishibuchi I; Ibuki Y; Yamakita I; Kurokawa T; Nagata Y; Okada M
World J Surg; 2018 May; 42(5):1496-1505. PubMed ID: 29030675
[TBL] [Abstract][Full Text] [Related]
68. Tumor recurrence and in-field control after multimodality treatment of locally advanced esophageal cancer.
Thoen H; Ceelen W; Boterberg T; Van Daele E; Pattyn P
Radiother Oncol; 2015 Apr; 115(1):16-21. PubMed ID: 25818394
[TBL] [Abstract][Full Text] [Related]
69. Influence of tumor response and treatment schedule on the distribution of tumor recurrence in esophageal cancer patients treated with neoadjuvant chemoradiotherapy.
Jipping KM; Hulshoff JB; van Amerongen EA; Bright TI; Watson DI; Plukker JTM
J Surg Oncol; 2017 Dec; 116(8):1096-1102. PubMed ID: 28853141
[TBL] [Abstract][Full Text] [Related]
70. Prognostic value of recurrence pattern in locally advanced esophageal squamous cell carcinoma: Results from the phase III trial NEOCRTEC5010.
Chen D; Kong M; Sun J; Yang H; Chen Y; Fang W; Yu Z; Mao W; Xiang J; Han Y; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Yang H; Li T; Zhang X; Li Q; Wang G; Mao T; Guo X; Lin T; Liu M; Witharana P; Fu J; Chen B; Shen J; Zhu C
J Thorac Cardiovasc Surg; 2023 Mar; 165(3):888-897. PubMed ID: 36137841
[TBL] [Abstract][Full Text] [Related]
71. Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma.
Xi M; Hallemeier CL; Merrell KW; Liao Z; Murphy MAB; Ho L; Hofstetter WL; Mehran R; Lee JH; Bhutani MS; Weston B; Maru DM; Komaki R; Ajani JA; Lin SH
Ann Surg; 2018 Aug; 268(2):289-295. PubMed ID: 28628563
[TBL] [Abstract][Full Text] [Related]
72. Safety and Feasibility of Robot-Assisted Minimally Invasive Esophagectomy (RAMIE) with Three-Field Lymphadenectomy and Neoadjuvant Chemoradiotherapy in Patients with Resectable Esophageal Cancer and Cervical Lymph Node Metastasis.
van der Horst S; Weijs TJ; Braunius WW; Mook S; Mohammed NH; Brosens L; van Rossum PSN; Weusten BLAM; Ruurda JP; van Hillegersberg R
Ann Surg Oncol; 2023 May; 30(5):2743-2752. PubMed ID: 36707482
[TBL] [Abstract][Full Text] [Related]
73. Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study.
Markar SR; Gronnier C; Pasquer A; Duhamel A; Beal H; Théreaux J; Gagnière J; Lebreton G; Brigand C; Meunier B; Collet D; Mariette C;
Eur J Cancer; 2016 Mar; 56():59-68. PubMed ID: 26808298
[TBL] [Abstract][Full Text] [Related]
74. Intensified Neoadjuvant Chemoradiotherapy for Patients with Potentially Resectable Esophageal Cancer: A Retrospective Cohort Study.
Boers J; Joldersma A; van Dalsen AD; Wiegman EM; Schenk BE; de Graaf JC; Pierik EGJM; Timmer PR; de Groot JWB
Ann Surg Oncol; 2020 May; 27(5):1520-1528. PubMed ID: 31828691
[TBL] [Abstract][Full Text] [Related]
75. Retrospective analysis of neoadjuvant chemotherapy followed by surgery versus definitive chemoradiotherapy with proton beam for locally advanced esophageal squamous cell carcinoma.
Ogawa K; Ishikawa H; Hisakura K; Hiroshima Y; Moriwaki T; Yamada T; Yamamoto Y; Akashi Y; Owada Y; Ohara Y; Enomoto T; Furuya K; Doi M; Shimomura O; Takahashi K; Hashimoto S; Sakurai H; Oda T
Int J Clin Oncol; 2021 Oct; 26(10):1856-1863. PubMed ID: 34241725
[TBL] [Abstract][Full Text] [Related]
76. Survival outcomes of consolidation chemoradiotherapy in esophageal cancer patients who achieve clinical complete response but refuse surgery after neoadjuvant chemoradiotherapy.
Fang HY; Chao YK; Chang HK; Tseng CK; Liu YH
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27878893
[TBL] [Abstract][Full Text] [Related]
77. Impact of neoadjuvant chemoradiotherapy on postoperative course after curative-intent transthoracic esophagectomy in esophageal cancer patients.
Bosch DJ; Muijs CT; Mul VE; Beukema JC; Hospers GA; Burgerhof JG; Plukker JT
Ann Surg Oncol; 2014 Feb; 21(2):605-11. PubMed ID: 24100962
[TBL] [Abstract][Full Text] [Related]
78. Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection.
Nakamura T; Ota M; Narumiya K; Sato T; Ohki T; Yamamoto M; Mitsuhashi N
Ann Surg Oncol; 2008 Sep; 15(9):2451-7. PubMed ID: 18592318
[TBL] [Abstract][Full Text] [Related]
79. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study.
Zhang X; Eyck BM; Yang Y; Liu J; Chao YK; Hou MM; Hung TM; Pang Q; Yu ZT; Jiang H; Law S; Wong I; Lam KO; van der Wilk BJ; van der Gaast A; Spaander MCW; Valkema R; Lagarde SM; Wijnhoven BPL; van Lanschot JJB; Li Z
BMC Cancer; 2020 Mar; 20(1):194. PubMed ID: 32143580
[TBL] [Abstract][Full Text] [Related]
80. Failure pattern of elective nodal irradiation for esophageal squamous cell cancer treated with neoadjuvant chemoradiotherapy.
Zhou S; Zhang L; Luo L; Li Q; Shen J; Feng Z; Feng Y; Yang H; Liu M; Xi M
Jpn J Clin Oncol; 2018 Sep; 48(9):815-821. PubMed ID: 30053015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
